Skip to main content
. Author manuscript; available in PMC: 2016 Sep 22.
Published in final edited form as: Oncogene. 2016 Jan 25;35(35):4633–4640. doi: 10.1038/onc.2015.527

Figure 4. The expression of WASF3 is upregulated following extended treatment of HER2-positive breast cancer cells with NRG.

Figure 4

Short term treatment (10–20 minutes) of SKBR3 cells with NRG does not lead to a significant increase in levels of WASF3, while longer term treatment (8–12 hours) leads to increased WASF3 levels (a). When starved SKBR3 cells are treated with NRG, there is an increase in WASF3 levels not seen in EGF treated cells (b). Treatment of MDA-MB-231 (MDA231) and MCF7 cells with NRG that do not express HER2 does not lead to any significant increase in WASF3 protein levels (c). RT-PCR analysis of expression levels of the WASF3 in SKBR3 cells shows a dramatic increase in WASF3 expression after 12 hours compared with 30 minutes, while WASF2 levels are not affected (d). NRG treatment also leads to a significant increase in WASF1 expression levels (d). When luciferase levels were studied (e) following NRG treatment of SKBR3 cells expressing high levels of the WASF3 promoter construct (−1101), high-level stimulation is seen compared with the WASF3 reporter construct (−747) which does not contain the STAT3 binding sites. ** p<0.01; Student’s t-test.